The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ALKERMES PLC | COM | G01767105 | 34,538 | 1,103,451 | SH | SOLE | 1,395,797 | 0 | 0 | |||
| BIOGEN INC | COM | 09062X103 | 50,369 | 176,826 | SH | SOLE | 177,126 | 0 | 0 | |||
| CARDINAL HEALTH INC | COM | 14149Y108 | 33,451 | 353,714 | SH | SOLE | 353,278 | 0 | 0 | |||
| EAGLE PHARMACEUTICALS INC | COM | 269796108 | 2,205 | 113,437 | SH | SOLE | 113,737 | 0 | 0 | |||
| EMBECTA CORP | COM | 29082K105 | 23,129 | 1,070,810 | SH | SOLE | 1,062,123 | 0 | 0 | |||
| ENANTA PHARMACEUTICALS INC | COM | 29251M106 | 14,715 | 687,613 | SH | SOLE | 603,301 | 0 | 0 | |||
| EXELIXIS INC | COM | 30161Q104 | 40,775 | 2,133,703 | SH | SOLE | 2,135,868 | 0 | 0 | |||
| KODIAK SCIENCES INC | COM | 50015M109 | 2,378 | 344,634 | SH | SOLE | 459,489 | 0 | 0 | |||
| REGENERON PHARMACEUTICALS | COM | 75886F107 | 42,529 | 59,188 | SH | SOLE | 59,488 | 0 | 0 | |||
| TARO PHARMACEUTICAL INDUS | COM | M8737E108 | 24,392 | 643,080 | SH | SOLE | 641,910 | 0 | 0 | |||
| UNITED THERAPEUTICS CORP | COM | 91307C102 | 44,749 | 202,715 | SH | SOLE | 202,110 | 0 | 0 | |||
| VANDA PHARMACEUTICALS INC | COM | 921659108 | 2,392 | 362,951 | SH | SOLE | 361,560 | 0 | 0 | |||